On January 19, 2024, Alector, Inc., a clinical-stage biotechnology company pioneering immuno-neurology, announced the closing of its underwritten public offering of 10,869,566 shares of its common stock. Alector has granted the underwriter a 30-day option to purchase up to an additional 1,630,434 shares of its common stock. The gross proceeds to Alector from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are approximately $75 million.​

Wilson Sonsini Goodrich & Rosati represented Alector in the transaction. The team includes:​

Corporate
Ken Clark
Michael Coke
Jacie Valentine
Sasha Bobrowicz
Elise Wu

Tax
Myra Sutanto Shen
Anjali Krishnan

FDA/Regulatory
Eva Yin

Fintech
Marc Foster

For more information, please see Alector's press release.